|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HPGDS |
Gene summary for HPGDS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HPGDS | Gene ID | 27306 |
| Gene name | hematopoietic prostaglandin D synthase | |
| Gene Alias | GSTS | |
| Cytomap | 4q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0001516 | UniProtAcc | O60760 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27306 | HPGDS | CA_HPV_1 | Human | Cervix | CC | 4.68e-22 | -6.52e-01 | 0.0264 |
| 27306 | HPGDS | CA_HPV_3 | Human | Cervix | CC | 5.74e-03 | -3.29e-01 | 0.0414 |
| 27306 | HPGDS | N_HPV_2 | Human | Cervix | N_HPV | 4.54e-06 | -5.01e-01 | -0.0131 |
| 27306 | HPGDS | CCI_1 | Human | Cervix | CC | 1.62e-02 | -7.06e-01 | 0.528 |
| 27306 | HPGDS | CCI_2 | Human | Cervix | CC | 7.14e-05 | -7.67e-01 | 0.5249 |
| 27306 | HPGDS | CCI_3 | Human | Cervix | CC | 1.02e-07 | -7.67e-01 | 0.516 |
| 27306 | HPGDS | CCII_1 | Human | Cervix | CC | 3.27e-11 | -7.67e-01 | 0.3249 |
| 27306 | HPGDS | Tumor | Human | Cervix | CC | 1.21e-28 | -7.67e-01 | 0.1241 |
| 27306 | HPGDS | sample1 | Human | Cervix | CC | 3.71e-09 | -7.67e-01 | 0.0959 |
| 27306 | HPGDS | sample3 | Human | Cervix | CC | 7.30e-28 | -7.67e-01 | 0.1387 |
| 27306 | HPGDS | H2 | Human | Cervix | HSIL_HPV | 7.55e-26 | -7.62e-01 | 0.0632 |
| 27306 | HPGDS | L1 | Human | Cervix | CC | 2.00e-12 | -7.67e-01 | 0.0802 |
| 27306 | HPGDS | T1 | Human | Cervix | CC | 2.56e-21 | -7.67e-01 | 0.0918 |
| 27306 | HPGDS | T2 | Human | Cervix | CC | 1.58e-04 | -7.67e-01 | 0.0709 |
| 27306 | HPGDS | T3 | Human | Cervix | CC | 4.34e-27 | -7.67e-01 | 0.1389 |
| 27306 | HPGDS | EOLP-1 | Human | Oral cavity | EOLP | 8.29e-15 | 6.66e-01 | -0.0202 |
| 27306 | HPGDS | EOLP-2 | Human | Oral cavity | EOLP | 4.47e-31 | 1.07e+00 | -0.0203 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00464564 | Cervix | CC | icosanoid biosynthetic process | 15/2311 | 56/18723 | 2.60e-03 | 1.80e-02 | 15 |
| GO:00015165 | Cervix | CC | prostaglandin biosynthetic process | 9/2311 | 31/18723 | 1.04e-02 | 4.97e-02 | 9 |
| GO:00464575 | Cervix | CC | prostanoid biosynthetic process | 9/2311 | 31/18723 | 1.04e-02 | 4.97e-02 | 9 |
| GO:004645611 | Cervix | HSIL_HPV | icosanoid biosynthetic process | 10/737 | 56/18723 | 5.80e-05 | 1.40e-03 | 10 |
| GO:000151611 | Cervix | HSIL_HPV | prostaglandin biosynthetic process | 7/737 | 31/18723 | 1.64e-04 | 3.14e-03 | 7 |
| GO:004645711 | Cervix | HSIL_HPV | prostanoid biosynthetic process | 7/737 | 31/18723 | 1.64e-04 | 3.14e-03 | 7 |
| GO:00066927 | Cervix | HSIL_HPV | prostanoid metabolic process | 8/737 | 49/18723 | 5.99e-04 | 8.37e-03 | 8 |
| GO:00066937 | Cervix | HSIL_HPV | prostaglandin metabolic process | 8/737 | 49/18723 | 5.99e-04 | 8.37e-03 | 8 |
| GO:00065755 | Cervix | HSIL_HPV | cellular modified amino acid metabolic process | 16/737 | 188/18723 | 3.18e-03 | 2.89e-02 | 16 |
| GO:00066907 | Cervix | HSIL_HPV | icosanoid metabolic process | 12/737 | 123/18723 | 3.36e-03 | 3.04e-02 | 12 |
| GO:00067495 | Cervix | HSIL_HPV | glutathione metabolic process | 8/737 | 64/18723 | 3.51e-03 | 3.15e-02 | 8 |
| GO:00066362 | Cervix | HSIL_HPV | unsaturated fatty acid biosynthetic process | 7/737 | 51/18723 | 3.65e-03 | 3.25e-02 | 7 |
| GO:004645621 | Cervix | N_HPV | icosanoid biosynthetic process | 7/534 | 56/18723 | 1.02e-03 | 1.20e-02 | 7 |
| GO:00464565 | Oral cavity | EOLP | icosanoid biosynthetic process | 14/2218 | 56/18723 | 4.81e-03 | 2.57e-02 | 14 |
| GO:000663611 | Oral cavity | EOLP | unsaturated fatty acid biosynthetic process | 13/2218 | 51/18723 | 5.43e-03 | 2.82e-02 | 13 |
| GO:00015166 | Oral cavity | EOLP | prostaglandin biosynthetic process | 9/2218 | 31/18723 | 8.00e-03 | 3.78e-02 | 9 |
| GO:00464576 | Oral cavity | EOLP | prostanoid biosynthetic process | 9/2218 | 31/18723 | 8.00e-03 | 3.78e-02 | 9 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HPGDS | SNV | Missense_Mutation | novel | c.318G>T | p.Glu106Asp | p.E106D | O60760 | protein_coding | tolerated(0.16) | benign(0.438) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HPGDS | SNV | Missense_Mutation | c.191G>T | p.Ser64Ile | p.S64I | O60760 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E9-A1RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| HPGDS | SNV | Missense_Mutation | c.46N>A | p.Glu16Lys | p.E16K | O60760 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HPGDS | SNV | Missense_Mutation | novel | c.415N>A | p.Glu139Lys | p.E139K | O60760 | protein_coding | tolerated(0.61) | benign(0.036) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| HPGDS | SNV | Missense_Mutation | novel | c.217A>C | p.Lys73Gln | p.K73Q | O60760 | protein_coding | tolerated(0.09) | benign(0.107) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| HPGDS | SNV | Missense_Mutation | c.149N>G | p.Lys50Arg | p.K50R | O60760 | protein_coding | tolerated(0.15) | probably_damaging(0.986) | TCGA-DC-6158-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HPGDS | insertion | Frame_Shift_Ins | novel | c.217_218insC | p.Lys73ThrfsTer17 | p.K73Tfs*17 | O60760 | protein_coding | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| HPGDS | SNV | Missense_Mutation | c.462N>T | p.Glu154Asp | p.E154D | O60760 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| HPGDS | SNV | Missense_Mutation | rs377241527 | c.33N>A | p.Met11Ile | p.M11I | O60760 | protein_coding | tolerated(0.09) | benign(0.061) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| HPGDS | SNV | Missense_Mutation | novel | c.437N>C | p.Val146Ala | p.V146A | O60760 | protein_coding | tolerated(0.06) | probably_damaging(0.998) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 27306 | HPGDS | ENZYME, DRUGGABLE GENOME | Praziquantel | PRAZIQUANTEL | ||
| 27306 | HPGDS | ENZYME, DRUGGABLE GENOME | inhibitor | 178103274 | CHEMBL574003 | |
| 27306 | HPGDS | ENZYME, DRUGGABLE GENOME | HF-0220 | |||
| 27306 | HPGDS | ENZYME, DRUGGABLE GENOME | HQL-79 | CHEMBL574003 | 20684598 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |